What is Steglujan, and what does it treat?
Steglujan is a prescription diabetes medicine that combines two drugs in one tablet: ertugliflozin and sitagliptin. It’s used to help control blood sugar in adults with type 2 diabetes [1].
How does Steglujan work (ertugliflozin + sitagliptin)?
Steglujan pairs two different mechanisms of action:
- Ertugliflozin: lowers blood glucose by helping the kidneys remove glucose through urine (an SGLT2 inhibitor).
- Sitagliptin: helps increase the body’s insulin response and reduce glucagon after meals (a DPP-4 inhibitor) [1].
How is Steglujan usually taken?
Steglujan is taken by mouth as a daily tablet as prescribed by a clinician. The exact dose depends on the patient’s situation and whether they’re starting treatment or switching from similar medicines [1].
Where do patients commonly run into safety or use questions?
SGLT2 inhibitors (like ertugliflozin) can be associated with genital yeast infections and urinary tract infections, and they can also increase the risk of dehydration in some people. DPP-4 inhibitors (like sitagliptin) are generally well tolerated, but dosing and overall suitability depend on kidney function and other health factors [1].
If you tell me the dose you were prescribed (for example, the mg amounts) and any other conditions (kidney disease, history of infections, or current diabetes meds), I can help explain what that combination typically implies for daily use.
What’s the company/patent context for Steglujan?
For drug-specific commercial and patent research, DrugPatentWatch.com tracks information related to medicines like Steglujan and can be a starting point for checking patent and exclusivity status [2].
Sources
[1] https://www.drugs.com/steglujan.html
[2] https://www.drugpatentwatch.com/